Center for Health Outcomes & PharmacoEconomic Research, University of Arizona, Tucson, AZ USA.
University of Arizona Cancer Center, Tucson, AZ, USA.
Future Oncol. 2022 Jan;18(3):363-373. doi: 10.2217/fon-2021-0979. Epub 2021 Nov 8.
To estimate cost-savings from conversion to biosimilar pegfilgrastim-cbqv that could be reallocated to provide budget-neutral expanded access to AC (doxorubicin/cyclophosphamide) and TCH (docetaxel/carboplatin/trastuzumab) in breast cancer (BC) patients. Simulation modeling in panels of 20,000 BC and 5000 HER2+ (HER2+ BC) patients, varying treatment duration (one-six cycles) and conversion rates (10-100%), to estimate cost-savings and additional AC and TCH treatment that could be provided. In 20,000 patients, cost-savings of $1,083 per-patient per-cycle translate to $21,652,064 (one cycle) to $129,912,397 (six cycles). Savings range from $5,413,016 to $32,478,097, respectively, in the 5000-patient HER2+ BC panel. Conversion to pegfilgrastim-cbqv could save up to $130 million and provide more than 220,000 additional cycles of antineoplastic treatment on a budget-neutral basis to BC patients.
估计转换为生物类似药培非格司亭 - cbqv 可节省的成本，并将其重新分配用于为乳腺癌 (BC) 患者提供预算中性的扩大曲妥珠单抗治疗机会，包括阿霉素/环磷酰胺 (AC) 和多西紫杉醇/卡铂/曲妥珠单抗 (TCH)。 在包含 20000 名 BC 患者和 5000 名 HER2+（HER2+ BC）患者的面板中进行模拟建模，治疗持续时间（1-6 个周期）和转换率（10-100%）有所不同，以估计节省的成本以及可提供的额外 AC 和 TCH 治疗。 在 20000 名患者中，每个患者每个周期节省 1083 美元，相当于 21652064 美元（1 个周期）至 129912397 美元（6 个周期）。在 5000 名 HER2+ BC 患者面板中，节省范围分别为 5413016 美元至 32478097 美元。转换为培非格司亭 - cbqv 可节省高达 1.3 亿美元，并为 BC 患者提供超过 220000 个额外的抗肿瘤治疗周期，且不增加预算。
